This review evaluates MXene structural integration and performance mechanisms in self-powered electrochemical sensors (SPECSs), focusing on active component function, maximum power output, long-term stability, and analytical sensitivity.
Phosphorylated Tau proteins are promising biomarkers for the diagnosis and prognosis of Alzheimer's disease. This study presents a novel voltametric sensor using a vanadium MXene polydopamine (VxPDA) redox active composite and a Tau-441-specific polyaniline molecularly imprinted polymer (PANI MIP) for the sensitive detection of Tau-441 in interstitial fluid (ISF) and plasma. The VxPDA/PANI MIP sensor demonstrates a broad detection range of 5 fg/mL to 5 ng/mL (122 aM/L to 122 pM/L) in ISF without the use of redox mediators, with a lower limit of detection (LOD) of 2.3 fg/mL (60 aM/L). Furthermore, a handheld device utilizing this technology successfully detects Tau-441 in artificial serum with high sensitivity (5 fg/mL to 150 fg/mL (122 aM/L to 366 aM/L)) and specificity within a clinically relevant range. The rapid detection time (∼32 min) and low cost (∼£20/device) of this sensor highlight its potential for minimally invasive, early AD diagnosis in clinical settings. This advancement aims to facilitate a transition away from invasive cerebrospinal fluid (CSF)-based diagnostic techniques for AD.
Early diagnosis of Alzheimer's disease (AD) is hindered by the high cost, complexity, and centralization of current diagnostic platforms such as enzyme‐linked immunosorbent assay (ELISA) and single‐molecule array (SIMOA). Here, an integrated point‐of‐care (PoC) biosensing platform is reported based on redox‐active polyphenol red molecularly imprinted polymers (pPhR MIPs) deposited on highly porous gold (HPG) electrodes for the ultrasensitive, reagent‐free detection of phosphorylated tau 181 (p‐tau 181) in undiluted plasma and serum. The unique electrochemical interface combines the signal‐enhancing properties of HPG with the redox functionality of pPhR, eliminating the need for external redox probes. The resulting sensor achieves a limit of detection (LOD) of 980 fg mL −1 and sensitivity of 4.39 µA/(pg mL −1 ), rivalling high‐end lab‐based assays while operating at a fraction of the cost. The platform integrates a low‐cost, handheld potentiostat and a machine learning (ML)‐enabled web app for real‐time data classification and regression, achieving 100% classification accuracy with zero false positives or negatives. The system demonstrates compatibility with both ethylenediaminetetraacetic acid (EDTA) and heparin‐treated samples and maintains accuracy in complex matrices. This work represents a step toward World Health Organization (WHO)‐compliant, decentralized diagnostics for neurodegenerative disease, offering a scalable foundation for future multianalyte platforms targeting AD and related disorders.